Journal of Virology, August 1999, p. 6209-6219, Vol. 73, No. 8
Institute of Molecular and Cell Biology,
Singapore 117 609, Singapore
Received 12 February 1999/Accepted 19 April 1999
The transforming proteins of the small DNA tumor viruses, simian
virus 40 (SV40), adenovirus, and human papillomavirus (HPV) target a
number of identical cellular regulators whose functional abrogation is
required for transformation. However, while both adenovirus E1A and
SV40 large T transforming properties also depend on the targeting
of the transcriptional coactivator CBP/p300, no such interaction has
been described for the HPV oncoprotein E6 or E7. Here, we demonstrate
that the HPV-16 E6 protein, previously shown to facilitate the
degradation of p53 in a complex with E6-associated protein (E6AP), also
targets CBP/p300 in an interaction involving the
C-terminal zinc finger of E6 and CBP residues 1808 to 1826. Furthermore, this interaction is limited to E6 proteins of high-risk HPVs associated with cervical cancer that have the capacity to repress
p53-dependent transcription. An HPV-16 E6 mutant (L50G) that binds
CBP/p300, but not E6AP, is still capable of down-regulating p53
transcriptional activity. Thus, HPV E6 proteins possess two distinct
mechanisms by which to abrogate p53 function: the repression of p53
transcriptional activity by targeting the p53 coactivator CBP/p300, and
the removal of cellular p53 protein through the proteosome degradation pathway.
The small DNA tumor viruses
represented by simian virus 40 (SV40), adenoviruses, and human
papillomaviruses (HPVs) have been the subject of intense study since
their interactions with cellular targets provide insights into the
processes involved in oncogenesis (16, 26, 40, 76). In the
case of HPVs, certain types, such as HPV type 16 (HPV-16) and HPV-18,
which are described as "high risk," are associated with invasive
cervical carcinoma, while other types, exemplified by HPV-6 and
HPV-11, that are associated with benign lesions are described as
"low risk" (9, 85). A comparison of functional
differences between high-risk and low-risk HPV proteins is particularly
useful in identifying important targets in tumorigenesis.
All three of these small DNA tumor viruses target regulators of the
cell cycle in order to promote cell proliferation and a suitable
environment for viral replication. Two of the proteins targeted for
this purpose are the retinoblastoma gene product (pRB) and p53, both
important inhibitors of cell cycle progression (77). By
interacting with pRB, the adenovirus E1A protein (Ad E1A)
(80), the SV40 large T antigen (SV40 TAg) (14),
and the HPV E7 protein (17, 51) promote the dissociation of
E2F from pRB (4, 10), thus inducing the expression of
S-phase-specific genes (15). Targeting of the p53 protein by
the adenovirus E1B 55-kDa protein (64), SV40 TAg (39,
46), and HPV E6 (79), appears to be equally important.
This is illustrated by studies of retinal photoreceptor cell fate in
transgenic mice (25, 59). In those cells in which only pRB
has been deregulated (for example, by expression of the HPV-16 E7
protein), p53-dependent apoptosis is observed. Those cells expressing
HPV E7 but lacking p53 gene expression, however, do not undergo
apoptosis and may go on instead to form retinoblastomas
(25). Identical results are observed when the absence of p53
gene expression is replaced by the coexpression of HPV-16 (16E6)
(59). Together these results provide a convincing argument
for the need to abolish p53 activity if pRB function has been abrogated
and the virus is to avoid inducing host cell death. An important
consequence of this viral strategy is that host cells in which p53
function has been abolished are compromised in the ability to mediate a
response to the induction of DNA damage (19, 32, 68, 74).
Subsequently, this may result in the accumulation of genetic changes
that are associated with tumorigenesis.
The mechanism by which 16E6 down-regulates p53 activity has been shown
to involve the active promotion of p53 degradation through the
ubiquitin-dependent proteolytic pathway (28, 66, 70). 16E6
achieves this by forming a complex with E6-associated protein (E6AP), a
cellular protein that acts as a ubiquitin ligase (65). The
ability to form an E6-E6AP-p53 complex appears to be limited to
high-risk E6 proteins (28, 79).
Another important cellular target of the Ad E1A and SV40 TAg
proteins is the transcriptional coactivator CBP/p300 (2, 18, 47). Through the interaction with specific transcription factors, CBP/p300 regulates a variety of signal-modulated events
(29). The mechanisms by which CBP/p300 activates gene
expression include (i) the ability to modify histones and nonhistone
transcription factors through intrinsic or associated acetyltransferase
activity (6, 23, 58, 83) and (ii) bridging the gap between
DNA-bound transcription factors and components of the general
transcription machinery (55).
Increasing evidence suggests that there is also a role for CBP/p300 in
the inhibition of cell cycle progression and cellular differentiation
(20). This may explain, at least in part, why CBP/p300 is
the target of SV40 and Ad E1A proteins. Recently published data have
also demonstrated that CBP/p300 activates p53-dependent transcription
(3, 24, 45, 67). Thus, part of the cell cycle-inhibitory
properties of CBP/p300 may result from its involvement in p53-regulated
events. Indeed, one mechanism by which SV40 and adenoviruses can
abrogate p53 function is by targeting the p53 cofactor CBP/p300, and at
least for Ad E1A, it has been shown that CBP-binding-deficient mutants
are no longer capable of down-regulating p53-dependent transcription
(24, 45, 67).
Interestingly, the down-regulation of p53-dependent transcription in
vivo is not limited to SV40 TAg and Ad E1A but has also been
demonstrated for high-risk HPV E6 proteins (49). However, to
date no interaction with the transcriptional coactivator CBP/p300 has
been described for the HPV E6 oncoprotein. It could be argued that the ability of high-risk HPV E6 proteins to degrade p53 through the E6AP pathway might be sufficient to explain the abrogation of p53
transcriptional activity. However, adenoviruses also possess the
capacity to degrade p53 via the E1B 55-kDa protein (63, 69)
and yet still target p53 transcriptional properties through an
E1A-CBP/p300 interaction.
For both SV40 and adenoviruses, the targeting of CBP/p300 has been
shown to be a prerequisite for transformation (18, 50, 81).
In the light of this, and the ability of E6 to interact with multiple
cellular targets (36), we wondered whether the 16E6 protein
might also target the transcriptional coactivator CBP/p300.
Here we provide evidence that HPV E6 proteins can indeed interact with
the transcriptional coactivator CBP/p300. In line with the observation
that CBP/p300 is an important target for the transformation process, we
also demonstrate that only E6 proteins from high-risk HPVs are capable
of binding CBP/p300. Finally, we provide evidence that the ability to
bind to CBP/p300 correlates with the down-regulation of p53
transcriptional activity in a manner similar to that of the Ad E1A protein.
Plasmid constructs.
The vector used for the expression of
glutathione S-transferase (GST) fusion proteins, unless
otherwise stated, was pGEX-2TKP (a modified version of the Pharmacia
pGEX-2TK vector containing a new polylinker), which was a gift
from T. Kouzarides. Also a gift from T. Kouzarides were plasmids
GST-CBP I (residues 461 to 662), GST-CBP II (residues 1621 to 1877),
GST-P/CAF, GST-E1A [1-90] (residues 1 to 90 of Ad E1A), G5E1BCAT,
pHK3NVP16, pHKnTCBP1VP16, pHKnCBP2VP16, and pHKGT. This
last construct contains the DNA binding domain of GAL4 (residues
1 to 147) driven by an SV40 promoter and was used to create the
GAL4-HPV E6 fusion proteins GAL-11E6 and GAL-16E6. Plasmids
GST-11E6 and GST-16E6 were created by inserting HPV-11 and HPV-16
E6 sequences amplified by PCR into pGEX2TKP. The GST-6E6 and
GST-18E6 constructs used to express the full-length HPV-6 and 18 E6,
proteins respectively, were a kind gift from D. Pim (60).
The GST-E6AP expression vector was kindly provided by P. Howley
(28). The GST-CBP constructs described in Fig. 2A were
created by cloning PCR-amplified fragments into pGEX2TKP. The maltose
binding protein (MBP)-CBP fusion construct was created by cloning a CBP
fragment (residues 1808 to 1852) from pGEX2TKP into the vector pMALP, a
modified version of pMAL (New England Biolabs [NEB]) containing a new
polylinker that was a gift from E. Manser. Also provided by E. Manser was the in vitro transcription and mammalian expression vector
pXJ-FLAG (48). The original DNA for the 16E6 mutant L50G was
a kind gift from T. Kanda (54) and was cloned via the
BamHI and XhoI restriction sites into pXJ-FLAG. All the other constructs used for in vitro transcription reactions were
cloned BamHI/HindIII into pXJ-FLAG.
Expression of recombinant bacterial fusion proteins.
GST
fusion and MBP fusion proteins were expressed in Escherichia
coli, extracted with lysis buffer (50 mM Tris-HCl [pH 8.0], 0.5 mM EDTA, 5 mM dithiothreitol [DTT], 15% glycerol, 1 mg of lysozyme
per ml, 1 mM phenylmethylsulfonyl fluoride), and, after sonication and
centrifugation, stored at Partial purification of CBP/p300 from HeLa nuclear extract.
HeLa nuclear extract was diluted 1:3 with 20 mM
morpholineethanesulfonic acid buffer (pH 6.1)-10 mM NaF-0.1% Triton
X-100 before being passed over a 0.2-ml SP Sepharose ion-exchange
column (Pharmacia) equilibrated with the same buffer. Elution of
CBP/p300 using a step gradient of increasing [KCl] was maximal in the
300 and 400 mM KCl fractions (as determined by Western blot analysis using an anti-p300 antibody [data not shown]). These two fractions were pooled and then diluted 1:7 with binding buffer (20 mM Tris-HCl [pH 8.0], 0.5 mM EDTA, 0.5 mM DTT, 20% glycerol, 01% Nonidet P-40 [NP-40]) to bring the final salt concentration down to 50 mM KCl. The
partially purified CBP/p300 was then passed over GST fusion protein
micro-affinity columns as described below.
Detection of protein-protein interactions by using micro-affinity
columns.
Bacterial lysate containing GST fusion protein was
incubated with glutathione Sepharose beads (Pharmacia) for 30 min at
4°C in 1× NENT buffer (100 mM NaCl, 1 mM EDTA, 0.5% NP-40, Tris-HCl [pH 8.0]). After spinning down and washing with 1 ml 1× NENT, the
beads were loaded into a yellow Gilson pipette tip containing a glass
bead (BDH catalog no. 332134Y) to create a 25-µl GST micro-column. For MBP micro-columns, a similar approach was taken in which amylose resin (NEB) was used in place of glutathione-Sepharose beads. These
columns were then used to detect interactions with in vitro-translated (IVT) and radiolabelled proteins, bacterially expressed fusion proteins, or partially purified nuclear CBP/p300.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Human Papillomavirus Type 16 E6 Oncoprotein Can
Down-Regulate p53 Activity by Targeting the Transcriptional
Coactivator CBP/p300
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
70°C.
-mercaptoethanol, 0.1% Tween 20, 0.5% milk) before being passed
over the GST micro-column. After washing the column twice with 200 µl
wash buffer (IPD buffer containing 150 mM KCl), proteins were eluted
from the column by adding 25 µl of 2× sodium dodecyl sulfate (SDS)
loading dye, heating to 95°C for 5 min, chasing with 25 µl water,
and spinning in a micro-centrifuge. Samples were then analyzed by
SDS-polyacrylamide gel electrophoresis (PAGE), and after staining and
drying of the gel, proteins were detected via exposure to
autoradiographic film.
Western blot analysis. Proteins analyzed by SDS-PAGE on 0.75-mm-thick gels were blotted onto PVDF membranes (NEN) overnight. The membranes were blocked with 5% (wt/vol) nonfat dry milk in TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween 20). A 1-h incubation at room temperature with the first monoclonal antibody was followed by washing with TSBT. The membrane was then incubated for 30 min with a horseradish peroxidase-coupled second antibody (1:4,000; DAKO) before washing in TSBT. Proteins were visualized with hyperfilm in the presence luminol (Amersham) for 10 to 60 s, depending on signal intensity. The commercially available monoclonal antibodies used in this study included the anti-p300 antibody p300 Ab-1 (Calbiochem), the anti-CBP/p300 antibody NM11 (Pharmingen), the anti-GST antibody B14 (Santa Cruz Biotechnology), and the anti-MBP antibody (NEB).
In vitro competition assays using recombinant proteins. For analysis of the disruption of in vitro binding of p53 and CBP by 16E6 protein, His-tagged p53 in bacterial lysate was first bound to nickel-nitrilotriacetic acid agarose beads (Qiagen) before incubation for 30 min with 3 µg of purified MBP-CBP II and a various amount of purified GST or GST-16E6 (0.5, 5, or 10 µg) in IPD buffer. After the beads were washed twice in IPD buffer containing an additional 200 mM KCl, proteins were eluted by heating the beads to 95°C in 2× SDS loading dye for 5 min. Samples were then run on an 10% SDS-polyacrylamide, gel and the proteins were subjected to Western blot analysis using an anti-MBP antibody (NEB).
Mammalian two hybrid-experiments. To study protein-protein interactions in vivo, we made use of a GAL4-VP16 chloramphenicol acetyltransferase (CAT) reporter system described previously (5). Full-length 11E6 and 16E6 sequences were fused to the DNA binding domain of GAL4, resulting in the constructs pGAL4-11E6 and pGAL4-16E6, respectively. U2-OS cells were cotransfected with 1 µg pGAL4-11E6 or pGAL4-16E6 and 4 µg pG5E1BCAT (a CAT reporter vector containing multiple GAL4 DNA binding sites). Cotransfected together with these plasmids was either pHK3NVP16 (the activation domain of VP16, residues 415 to 490, driven by the SV40 promoter), 2 µg of pHKnTCBP1VP16 (expressing CBP residues 461 to 662 in frame with the VP16 activation domain), or 2 µg of pHKnCBP2VP16 (expressing CBP residues 1621 to 1877 in frame with the VP16 activation domain); 48 h after transfection, the cells were harvested and CAT assays were performed as described below.
In vitro and in vivo p53 degradation assays. E6-mediated degradation of p53 was assayed by previously described methods (54, 65, 57a). For in vitro degradation of p53, 12.5 µl of IVT E6 protein was mixed with 2 µl of IVT 35S-labelled p53 in a total volume of 25 µl of assay buffer (25 mM Tris-HCl [pH 7.5], 100 mM NaCl, 3 mM DTT). The sample was then incubated at room temperature for 30, 90, or 180 min. At the indicated time points, the reaction was stopped by adding 2× SDS loading dye and boiling for 5 min. The samples were then analyzed by SDS-PAGE and autoradiography. In vivo degradation assays were performed as previously described (57a). U2-OS cells were transfected with 0.1 µg of a p53 expression vector and 1 µg of different E6-expressing vectors; 24 h after transfection, cells were shifted to medium containing 25 µg of cycloheximide per ml. Cells were harvested 0, 1, and 3 h after cycloheximide treatment as previously described (57a). Cell lysates were subjected to SDS-PAGE and analyzed by Western blotting using the anti-p53 antibody DO-1 (Santa Cruz).
Transfections and CAT assays.
U2-OS cells were plated onto
10-cm-diameter culture dishes and transfected at 50 to 70% confluency,
using Lipofectin reagent (GIBCO-BRL). For the p53 transcription
studies, 1 µg of the p53 reporter PG13CAT or the control vector
MG15CAT was cotransfected with 2 to 5 µg of expression vectors for
HPV E6 proteins, Ad E1A, or full-length CBP. Expression plasmids used
in transfections included those based on the expression vector pXJ-FLAG
(for E6 constructs), the Rous sarcoma virus-driven Ad5 12S E1A
expression plasmid pBJ9
(a gift from H. Land), and plasmid
pRc/RSV-mCBP.HA.RK (a gift from R. Goodman). CAT assays have
been described elsewhere (56), and the data
presented, unless otherwise stated, represent between three and eight
experiments using at least two independent DNA preparations.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
The 16E6 protein interacts with full-length nuclear CBP/p300. To determine whether the 16E6 protein could interact with CBP/p300, we partially purified these transcriptional coactivators from HeLa nuclear extract (see Materials and Methods) and then passed the fraction enriched for CBP/p300 over an E6 affinity column. Western blot analysis using the monoclonal antibodies p300 Ab-1 (Fig. 1A) and NM11 (data not shown) detected a specific interaction between CBP/p300 and GST-16E6. No interaction was detected for the control GST column, even though a greater amount of protein was used. Also shown in Fig. 1A is the interaction between full-length nuclear CBP/p300 and GST-P/CAF and GST-YY1, both of which have previously been shown to interact with CBP/p300 (43, 57, 83). These data provide the first evidence that a papillomavirus oncoprotein can associate with the transcriptional coactivator CBP/p300, although they do not provide information about the nature of the interaction.
|
Characterization of the HPV-16 E6-CBP interaction. To determine the E6 binding site within the CBP II domain, we used a number of GST-CBP constructs in micro-affinity column assays with IVT radiolabelled full-length HPV-16 E6 protein (Fig. 2A). We were able to identify a 19-amino-acid region of CBP (1808 to 1826) that was capable of binding full-length E6 (lane 7). Deletion into this sequence abolished binding to the E6 protein (lane 8). It can be seen from Fig. 2A that the 19-amino-acid sequence is virtually identical in both CBP and p300, with only one conservative change present, and a comparable level of conservation is also observed for CBP/p300 proteins from other species that are not shown here.
|
|
E6 proteins of high-risk but not low-risk HPV types bind CBP/p300. It has been suggested that functional differences between the E6 and E7 proteins of different HPV types represent a cardinal factor in their ability to transform cells and are reflected by their classification as either high-risk or low-risk types (8, 77, 85). In the case of other DNA tumor virus proteins, such as the Ad E1A protein and the SV40 TAg, interaction with the transcriptional coactivator CBP/p300 has been shown to be absolutely required for their transforming capabilities (18, 50, 81). If CBP/p300 is considered an important target in the transformation processes of other DNA tumor viruses, we postulated that an ability to target CBP/p300 might also be an important factor in distinguishing E6 proteins of high-risk from low-risk HPVs. Consequently, we compared the abilities the E6 proteins from two high-risk types (HPV-16 and HPV-18) to bind CBP with those from two low-risk types (HPV-6 and HPV-11).
In fact, Fig. 4A clearly demonstrates that only the GST-E6 proteins of the high-risk types (HPV-16 and HPV-18) bind to IVT CBP II, while those of the low-risk types (HPV-6 and HPV-11) fail to bind CBP. This observation is reproducible, as can be seen from the inability of IVT 11E6 protein to bind to a GST-CBP affinity column. Also shown in Fig. 4A is the inability of a chimeric 16/11 E6 protein to bind CBP II. In this E6 protein, all amino acids are from HPV-16 except those from positions 107 to 135, which represent HPV-11 sequences. This substitution mutation of 29 amino acids contained within a region of HPV-16 implicated in Fig. 3 to bind CBP again suggests a fundamental difference in the ability of E6 proteins from high-risk and low-risk types to bind CBP in vitro.
|
The down-regulation of p53 transcriptional activity by HPV-16 E6 correlates with CBP binding. One of the main functions proposed for E6 proteins of high-risk HPVs is the targeting of p53 in order to suppress apoptosis of the host cell (27, 53, 77). In the last few years, many lines of evidence have suggested that one way in which this might be achieved is by stimulating the degradation of p53 through the ubiquitination pathway (65, 66). Evidence has been provided both in vitro (28) and in vivo (70) that this activity is dependent on the interaction of E6 with a cellular factor termed E6AP which then acts as a ubiquitin ligase (65). The ability of E6 proteins to interact with E6AP has been shown to be limited to those of high-risk HPV types (79). It has also been reported previously that E6 proteins of high-risk but not low-risk types are able to down-regulate p53 transcriptional activity (49). One explanation for these observations is that down-regulation of p53-dependent transcription results from the E6AP-dependent degradation of p53.
Recently, it was also shown that p53-dependent transcription can be activated by CBP/p300 and that this activation can be abrogated by wild-type E1A but not a CBP-binding deficient mutant of E1A (3, 24, 45, 67). The results presented here have demonstrated that, like E1A, E6 proteins of high-risk HPVs can also target CBP/p300. We therefore examined whether the down-regulation of p53 transcriptional activity by E6 proteins could be achieved through the binding of CBP/p300 in a manner analogous to E1A. To answer this question, we required a 16E6 mutant that was deficient in targeting p53 for degradation through the E6AP pathway yet was still capable of binding CBP/p300. We assessed a number of existing 16E6 mutants before finding one with the desired properties. The 16E6 mutant L50G contains a point mutation in the first zinc finger of the E6 protein and has previously been shown to be p53 degradation deficient (54). Figure 5A demonstrates that this mutant is still able to interact with CBP in binding assays. However, when we tested this mutant for its ability to bind either E6AP or p53 in a similar assay, we found that it was deficient in this capacity (Fig. 5B). Furthermore, results in Fig. 5C confirm that this mutant, like the low-risk 11E6 protein, is unable to degrade p53 in standard in vitro and in vivo degradation assays (see Materials and Methods).
|
16E6 can inhibit the interaction between p53 and CBP. The work presented here and in our previous study (57a) indicates that 16E6 and p53 bind to the same motif (TRAM) in the CBP II domain. E1A, which also binds the CBP TRAM, can displace CBP from p53 (57a). We therefore tested whether the 16E6 protein could also displace CBP from p53. In Fig. 6 it can be seen that increasing concentrations of 16E6 do indeed inhibit the interaction between CBP and p53 in vitro, but not similar levels of GST protein alone. In this particular experiment, all three proteins used (His-p53, MBP-CBP II, and GST-16E6) are recombinant, bacterially expressed proteins, suggesting that this effect is direct and due to competitive binding between E6 and p53 for the CBP TRAM.
|
The repression of p53 transcriptional activity by 16E6 correlates with CBP binding and not p53 degradation. We next carried out a series of experiments in which we assessed the ability of the wild-type and L50G mutant HPV-16 E6 proteins to down-regulate p53-dependent transcription. U2-OS cells were transfected with the p53-responsive CAT reporter PG13CAT or the control vector MG15CAT, which contains mutated p53 binding sites. Cotransfected with PG13CAT were various expression plasmids coding for E6 proteins or Ad5 12S E1A. It can be seen from Fig. 7A that the PG13CAT vector is stimulated by endogenous p53 in U2-OS cells in a manner dependent on intact p53 binding sites. No effect on the level of transcriptional activity obtained with PG13CAT is seen upon the introduction of an expression vector containing full-length HPV-11 E6 sequences. By contrast, the expression of wild-type 16E6 protein results in a significant reduction in p53-dependent transcription. Consistent with our earlier analysis of the CBP binding domain within 16E6, the N-terminal 84 amino acids, which do not bind CBP, fail to repress p53 activity, while the C-terminal half of 16E6, which contains the CBP binding domain, can repress p53-dependent transcription, albeit slightly less efficiently than the full-length protein. Also shown for comparison is the level of repression of p53 activity obtained upon the introduction of the Ad5 12S E1A protein. Significantly, the 16E6 L50G mutant results in a similar level of transcriptional repression as wild-type 16E6. Thus, in this respect the 16E6 L50G mutant does not behave like a protein of a low-risk type but rather like wild-type 16E6. These data are consistent with the idea that by targeting CBP/p300, an E6 protein from a high-risk type can repress p53 transcriptional activity. Furthermore, the use of the 16E6 L50G mutant suggests that this ability is independent of E6AP-mediated degradation.
|
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
In the last few years, study of the transformation processes that are instigated by SV40 and adenoviruses has led to the discovery of a number of important cellular regulators as viral targets. This knowledge has often resulted in the confirmation of identical targets for the high-risk HPVs (17, 79). While both SV40 and adenovirus proteins have recently been shown to bind to the transcriptional adapter CBP/p300, no such interaction has been described for HPV oncoproteins. One possible explanation for this is that all previously known HPV functions that mirror Ad E1A and SV40 TAg properties have been found to be present in the HPV E7 protein. To date no interaction between HPV E7 and CBP/p300 has been described. Moreover, the recent finding that HPV E7 proteins bind to and abrogate the function of p21Cip1 in a p53-independent manner (19a, 31) has suggested that E7 might not need to affect p53 activation by targeting CBP/p300, since it can directly affect the function of this important downstream inhibitor of cell cycle progression.
We set about identifying whether the HPV E6 oncoprotein could interact with CBP/p300 for three reasons. First, we believed that since CBP/p300 represented an indispensable target for transformation by Ad E1A and SV40 TAg, it was likely that at least one of the HPV oncoproteins would also target CBP/p300. Second, both adenoviruses and SV40 abrogate p53 activity in more than one way: by affecting p53 directly and also indirectly through an interaction with the transcriptional cofactor CBP/p300. Third, since HPV E6 proteins of high-risk types had previously been shown to down-regulate p53 transcriptional activity, we felt that they might also bring about this effect through the targeting of the coactivator CBP/p300.
Here, for the first time, we have provided evidence that the E6 proteins of high-risk HPVs can bind CBP/p300, thus demonstrating an Ad E1A and SV40 TAg-like property for HPV E6. One reason why the E6-CBP/p300 interaction might not have been previously detected is that unlike E1A, which demonstrates an extremely high affinity for this transcriptional coactivator and binds multiple domains, 16E6 binds the CBP II domain with only moderate affinity. Coupled with this is the fact that any attempts to analyze HPV E6-CBP/p300 interactions using IVT full-length CBP/p300 would, from our experience, have failed to detect such an interaction. The inability of in vitro-expressed full-length CBP/p300 to interact with proteins that bind only the CBP II domain is not limited to E6. Similar observations are also seen for other proteins, such as c-Fos and YY1 (84). We interpret these results to imply that access to the CBP II domain, in the context of full-length CBP/p300, is probably dependent on posttranslational modification. For example, access to the CBP II domain might be dependent on phosphorylation, because CBP/p300 phosphorylation is a dynamic process regulated in a cell cycle-dependent manner (1, 33, 82). By partially purifying full-length CBP/p300 from HeLa cell nuclear extract, we have been able to overcome these obstacles and demonstrate the ability of 16E6 to bind full-length CBP/p300 as do other transcription factors that bind only the CBP II domain.
The 16E6 protein, although only 151 amino acids in length, has been shown to have multiple properties and interact with a plethora of cellular proteins (36, 53). These include, in addition to E6AP, (i) a calcium-binding protein (E6-BP) that may play a role in epithelial differentiation (11), (ii) the Bak protein, a regulator of the apoptosis pathway (71), (iii) the focal adhesion protein paxillin (75), (iv) the human homologue of the Drosophila discs large tumor suppressor protein, hDLG (34, 44), and (v) IRF-3, a transcriptional activator possibly involved in antiviral cellular responses (62). Interestingly, HPV E6 proteins have also been shown to stimulate telomerase activity (35), thus potentially lengthening the life span of the host cell in a manner that is likely to contribute to the transformation process (78). In light of the results presented here, we can now add the transcriptional coactivator CBP/p300 to this impressive list of interacting cellular proteins. One advantage of targeting an important transcriptional coactivator such as CBP/p300 is that it may result in an ability to control multiple signaling pathways. That is because, in addition to p53, CBP/p300 acts as a cofactor for many other cellular regulators. Such a strategy appears to have been adopted by the Ad E1A protein (57a) and could also apply to high-risk HPV E6 proteins.
Comparisons between the E6 and E7 proteins of high-risk and low-risk HPVs have indicated functional distinctions based on differential affinities for cellular target proteins. For example, differences have been observed for the binding of E7 to pRB and p21Cip1 (31, 52) and for E6 binding to p53 and E6AP (28, 79). The capacity to target negative regulators of cell growth almost certainly represents a critical factor in the ability of these proteins to transform cells. Our observation that CBP/p300 binding is limited to E6 proteins of high-risk HPVs suggests that this transcriptional coactivator may also represent an important target for the transformation process. Such an idea is consistent with the finding that CBP/p300-binding-deficient mutants of Ad E1A are no longer capable of transforming cells. This finding, together with the fact that all three small DNA tumor viruses target CBP/p300, adds weight to the idea that CBP/p300 may act as a tumor suppressor protein.
One important role of CBP/p300 in cell cycle inhibition is in the facilitation of p53-dependent gene expression. Previous observations have indicated that p53 transcriptional activity can be abrogated by E6 proteins of high-risk HPVs (49). One potential mechanism to explain this would be the promotion of p53 degradation through the E6-E6AP pathway. However, the results presented here in Fig. 5 and 7 show that an HPV-16 mutant (L50G) that can bind CBP/p300 but fails to bind E6AP and degrade p53 in vitro and in vivo is still capable of repressing p53 transcriptional activity. This finding suggests that for this particular property the correlation is with CBP/p300 binding and not with the promotion of p53 degradation through the E6AP pathway. However, the previous analysis that demonstrated the inability of the 16E6 mutant L50G, in conjunction with HPV-16 E7, to transform human embryonic kidney cells (54) suggests that E6AP-dependent degradation of p53 is still likely to be a prerequisite for the induction of cellular transformation. We therefore propose that the E6 proteins of high-risk HPVs target p53 in two ways. The first, which may be a more immediate response, is the abrogation of p53 transcriptional activity by binding to the cofactor CBP/p300. The second would consist of the removal of p53 protein through E6AP-dependent degradation. Together, these complementary functions of E6 could facilitate the effective elimination of cellular p53 activity. Support for such a proposal comes from a number of previous studies that utilize HPV E6 mutants and demonstrate an independence of different aspects of transcriptional regulation from the ability to promote p53 degradation (12, 13, 42, 73).
It is still not certain at this time exactly how E6 abrogates the CBP/p300-dependent activation of p53. However, it is interesting that all three DNA tumor virus proteins (Ad E1A, SV40 TAg, and 16E6) bind the same region of CBP, which is also the p53 binding site within the CBP II domain. Although we have not yet determined whether SV40 TAg binds the 19-amino-acid CBP TRAM present within CBP II, we have established that this is the binding site for p53, 16E6, and Ad E1A (this study and reference 57a). This finding, together with the fact that both 16E6 and the Ad E1A proteins can displace p53 from the CBP TRAM in vitro, suggests that inhibition of a p53-CBP TRAM interaction could represent an important part of the mechanism by which p53 function is abrogated. Other potential p53 binding sites within CBP/p300 have been described, however (22, 24), which makes it difficult to predict the outcome of such displacement.
An analysis of the primary amino acid sequence within the region of 16E6 (residues 100 to 142) implicated in Fig. 3 in binding CBP/p300 has not revealed any obvious similarities to those in Ad E1A or p53 that have previously been shown to bind the CBP TRAM (57a). However, there are some similarities to the bipartite CBP/p300 binding domain of SV40 previously described (18), although the significance of these observations, if any, has yet to be established.
CBP/p300 has been shown to activate transcription by at least two mechanisms: one involving acetylation of histone and nonhistone proteins, and one involving the bridging of DNA-bound transcription factors to components of the basal transcription machinery. HPV E6 proteins could potentially abrogate both of these mechanisms of activation by binding to the CBP II domain. Recent reports have indicated that as a consequence of p53 acetylation, CBP/p300 can indirectly increase the affinity of p53 for its cognate DNA binding sites (23). If HPV E6 (as well as Ad E1A and SV40 TAg) prevented this acetylation by interacting with CBP/p300, then the affinity of p53 for target promoters might be reduced. This represents a distinct possibility, since a number of reports have demonstrated that the presence of E6 proteins from high-risk HPVs significantly reduces p53 DNA binding activity (41, 72, 73). The CBP/p300-associated acetyltransferase, P/CAF, also binds to the CBP II region and has been shown to be displaced by Ad E1A (83). P/CAF promotes cell cycle inhibition and cellular differentiation processes through its acetyltransferase properties (61, 83). Thus, by binding to the CBP II domain, HPV E6 might also down-regulate these pathways in addition to its effect on p53. HPV E6 proteins might also target the bridging mechanism for CBP/p300-dependent activation. CBP/p300 was recently shown to activate CREB-dependent transcription by recruiting RNA helicase A, a component of an RNA polymerase II complex to a promoter containing a functional CRE site (55). Since RNA helicase A has also been shown to bind the CBP II domain, 16E6, along with Ad E1A and SV40 TAg, might also inhibit this particular mechanism of CBP/p300-dependent activation by binding to the CBP II domain. Similar possibilities exist for the disruption of CBP/p300-TFIIB interactions (38). Future studies should permit an analysis of these potential mechanisms.
Finally, both Ad E1A and SV40 TAg proteins depend on an interaction with CBP/p300 for their cellular transformation properties. Here, we have provided evidence that an ability to bind CBP/p300 is limited to E6 proteins of high-risk HPVs (Fig. 4). Taken together, these observations suggest a possible role for the E6-CBP/p300 interaction in HPV-mediated oncogenesis. Future studies should be able to assess the ability of CBP-binding-deficient mutants of 16E6 to contribute towards cellular transformation. This in turn should provide an insight into the potential clinical relevance of the 16E6-CBP/p300 interaction described here.
| |
ACKNOWLEDGMENTS |
|---|
We thank T. Kouzarides, R. Goodman, T. Kanda, E. Manser, E. Androphy, and D. Pim for plasmid constructs, Choon-Heng Koh for technical assistance, and Benjamin Li and Ed Manser for helpful discussions and critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: KuDOS Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge CB4 4GW, United Kingdom. Phone: 44-1223-719719. Fax: 44-1223-719720. E-mail: mjoconnor{at}kudospharma.co.uk.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
| 1. | Ait-Si-Ali, S., S. Ramirez, F. X. Barre, F. Dkhissi, L. Magnaghi-Jaulin, J. A. Girault, P. Robin, M. Knibiehler, L. L. Pritchard, B. Ducommun, D. Trouche, and A. Harel-Bellan. 1998. Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 396:184-186[Medline]. |
| 2. | Arany, Z., D. Newsome, E. Oldread, D. M. Livingston, and R. Eckner. 1995. A family of transcriptional adapter proteins targeted by the E1A oncoprotein. Nature 374:81-84[Medline]. |
| 3. | Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and K. Kelly. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175-1184[Medline]. |
| 4. | Bagchi, S., P. Raychaudhuri, and J. R. Nevins. 1990. Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell 62:659-669[Medline]. |
| 5. | Bannister, A. J., and T. Kouzarides. 1995. CBP-induced stimulation of c-Fos activity is abrogated by E1A. EMBO J. 14:4758-4762[Medline]. |
| 6. | Bannister, A. J., and T. Kouzarides. 1996. The CBP co-activator is a histone acetyltransferase. Nature 384:641-643[Medline]. |
| 7. |
Barbosa, M. S.,
D. R. Lowy, and J. T. Schiller.
1989.
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins.
J. Virol.
63:1404-1407 |
| 8. |
Barbosa, M. S.,
W. C. Vass,
D. R. Lowy, and J. T. Schiller.
1991.
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential.
J. Virol.
65:292-298 |
| 9. |
Bosch, F. X.,
M. M. Manos,
N. Munoz,
M. Sherman,
A. M. Jansen,
J. Peto,
M. H. Schiffman,
V. Moreno,
R. Kurman,
K. V. Shah,
E. Alihonou,
S. Bayo,
H. C. Mokhtar,
S. Chicareon,
A. Daudt,
E. Delosrios,
P. Ghadirian,
J. N. Kitinya,
M. Koulibaly,
C. Ngelangel,
L. M. P. Tintore,
J. L. Riosdalenz,
A. Sarjadi-Schneider,
L. Tafur,
A. R. Tayssie,
P. A. Rolon,
M. Torroella,
A. V. Tapia,
H. R. Wabinga,
W. Zatonski,
B. Sylla,
P. Vizcaino,
D. Magnin,
J. Kaldore,
C. Greer, and C. Wheeler.
1995.
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group.
J. Natl. Cancer Inst.
87:796-802 |
| 10. |
Chellappan, S.,
V. B. Kraus,
B. Kroger,
K. Munger,
P. M. Howley,
W. C. Phelps, and J. R. Nevins.
1992.
Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.
Proc. Natl. Acad. Sci. USA
89:4549-4553 |
| 11. |
Chen, J. J.,
C. E. Reid,
V. Band, and E. J. Androphy.
1995.
Interaction of papillomavirus E6 oncoproteins with a putative calcium- binding protein.
Science
269:529-531 |
| 12. | Crook, T., C. Fisher, P. J. Masterson, and K. H. Vousden. 1994. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9:1225-1230[Medline]. |
| 13. | Crook, T., J. A. Tidy, and K. H. Vousden. 1991. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556[Medline]. |
| 14. | DeCaprio, J. A., J. W. Ludlow, J. Figge, J. Y. Shew, C. M. Huang, W. H. Lee, E. Marsilio, E. Paucha, and D. M. Livingston. 1988. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283[Medline]. |
| 15. | DeGregori, J., T. Kowalik, and J. R. Nevins. 1995. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15:4215-4224[Abstract]. |
| 16. | Dyson, N., and E. Harlow. 1992. Adenovirus E1A targets key regulators of cell proliferation. Cancer Surv. 12:161-195[Medline]. |
| 17. |
Dyson, N.,
P. M. Howley,
K. Munger, and E. Harlow.
1989.
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.
Science
243:934-937 |
| 18. | Eckner, R., J. W. Ludlow, N. L. Lill, E. Oldread, Z. Arany, N. Modjtahedi, J. A. DeCaprio, D. M. Livingston, and J. A. Morgan. 1996. Association of p300 and CBP with simian virus 40 large T antigen. Mol. Cell. Biol. 16:3454-3464[Abstract]. |
| 19. |
Foster, S. A.,
G. W. Demers,
B. G. Etscheid, and D. A. Galloway.
1994.
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest.
J. Virol.
68:5698-5705 |
| 19a. |
Funk, J. O.,
S. Waga,
J. Harry,
E. Espling,
B. Stillman, and D. A. Galloway.
1997.
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein.
Genes Dev.
11:2090-2100 |
| 20. | Giles, R. H., D. J. Peters, and M. H. Breuning. 1998. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 14:178-183[Medline]. |
| 21. | Grossman, S. R., and L. A. Laimins. 1989. E6 protein of human papillomavirus type 18 binds zinc. Oncogene 4:1089-1093[Medline]. |
| 22. | Grossman, S. R., M. Perez, A. L. Kung, M. Joseph, C. Mansur, Z. X. Xiao, S. Kumar, P. M. Howley, and D. M. Livingston. 1998. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2:405-415[Medline]. |
| 23. | Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606[Medline]. |
| 24. | Gu, W., X. L. Shi, and R. G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819-823[Medline]. |
| 25. |
Howes, K. A.,
N. Ransom,
D. S. Papermaster,
J. G. Lasudry,
D. M. Albert, and J. J. Windle.
1994.
Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53.
Genes Dev.
8:1300-1310 |
| 26. | Howley, P. M., K. Munger, H. Romanczuk, M. Scheffner, and J. M. Huibregtse. 1991. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. Proc. Princess Takamatsu Symp. 22:239-248. |
| 27. |
Howley, P. M.,
M. Scheffner,
J. Huibregtse, and K. Munger.
1991.
Oncoproteins encoded by the cancer-associated human papillomaviruses target the products of the retinoblastoma and p53 tumor suppressor genes.
Cold Spring Harbor Symp. Quant. Biol.
56:149-155 |
| 28. | Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1991. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10:4129-4135[Medline]. |
| 29. | Janknecht, R., and T. Hunter. 1996. Transcription. A growing coactivator network. Nature 383:22-23[Medline]. |
| 30. | Janknecht, R., and T. Hunter. 1996. Versatile molecular glue. Curr. Biol. 6:951-954[Medline]. |
| 31. |
Jones, D. L.,
R. M. Alani, and K. Munger.
1997.
The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2.
Genes Dev.
11:2101-2111 |
| 32. |
Kessis, T. D.,
R. J. Slebos,
W. G. Nelson,
M. B. Kastan,
B. S. Plunkett,
S. M. Han,
A. T. Lorincz,
L. Hedrick, and K. R. Cho.
1993.
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.
Proc. Natl. Acad. Sci. USA
90:3988-3992 |
| 33. | Kitabayashi, I., R. Eckner, Z. Arany, R. Chiu, G. Gachelin, D. M. Livingston, and K. K. Yokoyama. 1995. Phosphorylation of the adenovirus E1A-associated 300 kDa protein in response to retinoic acid and E1A during the differentiation of F9 cells. EMBO J. 14:3496-3509[Medline]. |
| 34. |
Kiyono, T.,
A. Hiraiwa,
M. Fujita,
Y. Hayashi,
T. Akiyama, and M. Ishibashi.
1997.
Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.
Proc. Natl. Acad. Sci. USA
94:11612-11616 |
| 35. | Klingelhutz, A. J., S. A. Foster, and J. K. McDougall. 1996. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380:79-82[Medline]. |
| 36. | Kubbutat, M. H., and K. H. Vousden. 1998. New HPV E6 binding proteins: dangerous liaisons? Trends Microbiol. 6:173-175[Medline]. |
| 37. |
Kurokawa, R.,
D. Kalafus,
M. H. Ogliastro,
C. Kioussi,
L. Xu,
J. Torchia,
M. G. Rosenfeld, and C. K. Glass.
1998.
Differential use of CREB binding protein-coactivator complexes.
Science
279:700-703 |
| 38. | Kwok, R. P., J. R. Lundblad, J. C. Chrivia, J. P. Richards, H. P. Bachinger, R. G. Brennan, S. G. Roberts, M. R. Green, and R. H. Goodman. 1994. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370:223-226[Medline]. |
| 39. | Lane, D. P., and L. V. Crawford. 1979. T antigen is bound to a host protein in transformed cells. Nature 278:261-263[Medline]. |
| 40. | Lane, D. P., V. Simanis, R. Bartsch, J. Yewdell, J. Gannon, and S. Mole. 1985. Cellular targets for SV40 large T-antigen. Proc. R. Soc. Lond. Ser. B 226:25-42[Medline]. |
| 41. |
Lechner, M. S., and L. A. Laimins.
1994.
Inhibition of p53 DNA binding by human papillomavirus E6 proteins.
J. Virol.
68:4262-4273 |
| 42. | Lechner, M. S., D. H. Mack, A. B. Finicle, T. Crook, K. H. Vousden, and L. A. Laimins. 1992. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:3045-3052[Medline]. |
| 43. |
Lee, J. S.,
K. M. Galvin,
R. H. See,
R. Eckner,
D. Livingston,
E. Moran, and Y. Shi.
1995.
Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300.
Genes Dev.
9:1188-1198 |
| 44. |
Lee, S. S.,
R. S. Weiss, and R. T. Javier.
1997.
Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homologue of the Drosophila discs large tumor suppressor protein.
Proc. Natl. Acad. Sci. USA
94:6670-6675 |
| 45. | Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827[Medline]. |
| 46. | Linzer, D. I., and A. J. Levine. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52[Medline]. |
| 47. | Lundblad, J. R., R. P. Kwok, M. E. Laurance, M. L. Harter, and R. H. Goodman. 1995. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature 374:85-88[Medline]. |
| 48. |
Manser, E.,
H. Y. Huang,
T. H. Loo,
X. Q. Chen,
J. M. Dong,
T. Leung, and L. Lim.
1997.
Expression of constitutively active  -PAK reveals effects of the kinase on actin and focal complexes.
Mol. Cell. Biol.
17:1129-1143[Abstract].
|
| 49. | Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013-5020[Medline]. |
| 50. | Moran, E. 1993. DNA tumor virus transforming proteins and the cell cycle. Curr. Opin. Genet. Dev. 3:63-70[Medline]. |
| 51. | Munger, K., B. A. Werness, N. Dyson, W. C. Phelps, E. Harlow, and P. M. Howley. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8:4099-4105[Medline]. |
| 52. |
Munger, K.,
C. L. Yee,
W. C. Phelps,
J. A. Pietenpol,
H. L. Moses, and P. M. Howley.
1991.
Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences.
J. Virol.
65:3943-3948 |
| 53. | Myers, G., and E. J. Androphy. 1995. The E6 protein, p. 47-57. In G. Myers, H. U. Bernard, H. Delius, J. Icenogle, C. C. Baker, A. Halpern, and C. Wheeler (ed.), Human papillomaviruses. Los Alamos National Laboratory, Los Alamos, N.Mex. |
| 54. | Nakagawa, S., S. Watanabe, H. Yoshikawa, Y. Taketani, K. Yoshiike, and T. Kanda. 1995. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 212:535-542[Medline]. |
| 55. | Nakajima, T., C. Uchida, S. F. Anderson, C. G. Lee, J. Hurwitz, J. D. Parvin, and M. Montminy. 1997. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90:1107-1112[Medline]. |
| 56. | O'Connor, M., and H. U. Bernard. 1995. Oct-1 activates the epithelial-specific enhancer of human papillomavirus type 16 via a synergistic interaction with NFI at a conserved composite regulatory element. Virology 207:77-88[Medline]. |
| 57. |
O'Connor, M. J.,
S. H. Tan,
C. H. Tan, and H. U. Bernard.
1996.
YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity.
J. Virol.
70:6529-6539 |
| 57a. |
O'Connor, M. J.,
H. Zimmermann,
S. Nielsen,
H. U. Bernard, and T. Kouzarides.
1999.
Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300.
J. Virol.
73:3574-3581 |
| 58. | Ogryzko, V. V., R. L. Schiltz, V. Russanova, B. H. Howard, and Y. Nakatani. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959[Medline]. |
| 59. |
Pan, H., and A. E. Griep.
1994.
Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development.
Genes Dev.
8:1285-1299 |
| 60. | Pim, D., P. Massimi, and L. Banks. 1997. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 15:257-264[Medline]. |
| 61. | Puri, P. L., V. Sartorelli, X. J. Yang, Y. Hamamori, V. V. Ogryzko, B. H. Howard, L. Kedes, J. Y. Wang, A. Graessmann, Y. Nakatani, and M. Levrero. 1997. Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol. Cell 1:35-45[Medline]. |
| 62. |
Ronco, L. V.,
A. Y. Karpova,
M. Vidal, and P. M. Howley.
1998.
Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity.
Genes Dev.
12:2061-2072 |
| 63. |
Roth, J.,
C. Konig,
S. Wienzek,
S. Weigel,
S. Ristea, and M. Dobbelstein.
1998.
Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins.
J. Virol.
72:8510-8516 |
| 64. | Sarnow, P., Y. S. Ho, J. Williams, and A. J. Levine. 1982. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387-394[Medline]. |
| 65. | Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505[Medline]. |
| 66. | Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136[Medline]. |
| 67. | Somasundaram, K., and W. S. El-Deiry. 1997. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 14:1047-1057[Medline]. |
| 68. |
Song, S.,
G. A. Gulliver, and P. F. Lambert.
1998.
Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation- induced DNA damage responses in vivo through p53-dependent and p53- independent pathways.
Proc. Natl. Acad. Sci. USA
95:2290-2295 |
| 69. | Steegenga, W. T., N. Riteco, A. G. Jochemsen, F. J. Fallaux, and J. L. Bos. 1998. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16:349-357[Medline]. |
| 70. |
Talis, A. L.,
J. M. Huibregtse, and P. M. Howley.
1998.
The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells.
J. Biol. Chem.
273:6439-6445 |
| 71. | Thomas, M., and L. Banks. 1998. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17:2943-2954[Medline]. |
| 72. | Thomas, M., P. Massimi, and L. Banks. 1996. HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. Oncogene 13:471-480[Medline]. |
| 73. | Thomas, M., P. Massimi, J. Jenkins, and L. Banks. 1995. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene 10:261-268[Medline]. |
| 74. | Thompson, D. A., G. Belinsky, T. H. Chang, D. L. Jones, R. Schlegel, and K. Munger. 1997. The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene 15:3025-3035[Medline]. |
| 75. |
Tong, X., and P. M. Howley.
1997.
The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton.
Proc. Natl. Acad. Sci. USA
94:4412-4417 |
| 76. | Van Dyke, T. A. 1994. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin. Cancer Biol. 5:47-60[Medline]. |
| 77. | Vousden, K. H. 1995. Regulation of the cell cycle by viral oncoproteins. Semin. Cancer Biol. 6:109-116[Medline]. |
| 78. | Vousden, K. H. 1996. HPV E6: ensuring all's well at the end. Trends Microbiol. 4:337-338[Medline]. |
| 79. |
Werness, B. A.,
A. J. Levine, and P. M. Howley.
1990.
Association of human papillomavirus types 16 and 18 E6 proteins with p53.
Science
248:76-79 |
| 80. | Whyte, P., K. J. Buchkovich, J. M. Horowitz, S. H. Friend, M. Raybuck, R. A. Weinberg, and E. Harlow. 1988. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334:124-129[Medline]. |
| 81. |
Yaciuk, P.,
M. C. Carter,
J. M. Pipas, and E. Moran.
1991.
Simian virus 40 large-T antigen expresses a biological activity complementary to the p300-associated transforming function of the adenovirus E1A gene products.
Mol. Cell. Biol.
11:2116-2124 |
| 82. |
Yaciuk, P., and E. Moran.
1991.
Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification.
Mol. Cell. Biol.
11:5389-5397 |
| 83. | Yang, X. J., V. V. Ogryzko, J. Nishikawa, B. H. Howard, and Y. Nakatani. 1996. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319-324[Medline]. |
| 84. | Zimmermann, H., and M. O'Connor. Unpublished data. |
| 85. | zur Hausen, H. 1991. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9-13[Medline]. |
Journal of Virology, August 1999, p. 6209-6219, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Liu, X., Dakic, A., Zhang, Y., Dai, Y., Chen, R., Schlegel, R.
(2009). HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc. Natl. Acad. Sci. USA
106: 18780-18785
[Abstract] [Full Text] -
Kutluay, S. B., DeVos, S. L., Klomp, J. E., Triezenberg, S. J.
(2009). Transcriptional Coactivators Are Not Required for Herpes Simplex Virus Type 1 Immediate-Early Gene Expression In Vitro. J. Virol.
83: 3436-3449
[Abstract] [Full Text] -
Shamanin, V. A., Sekaric, P., Androphy, E. J.
(2008). hAda3 Degradation by Papillomavirus Type 16 E6 Correlates with Abrogation of the p14ARF-p53 Pathway and Efficient Immortalization of Human Mammary Epithelial Cells. J. Virol.
82: 3912-3920
[Abstract] [Full Text] -
Sekaric, P., Cherry, J. J., Androphy, E. J.
(2008). Binding of Human Papillomavirus Type 16 E6 to E6AP Is Not Required for Activation of hTERT. J. Virol.
82: 71-76
[Abstract] [Full Text] -
Hebner, C., Beglin, M., Laimins, L. A.
(2007). Human Papillomavirus E6 Proteins Mediate Resistance to Interferon-Induced Growth Arrest through Inhibition of p53 Acetylation. J. Virol.
81: 12740-12747
[Abstract] [Full Text] -
Filippova, M., Johnson, M. M., Bautista, M., Filippov, V., Fodor, N., Tungteakkhun, S. S., Williams, K., Duerksen-Hughes, P. J.
(2007). The Large and Small Isoforms of Human Papillomavirus Type 16 E6 Bind to and Differentially Affect Procaspase 8 Stability and Activity. J. Virol.
81: 4116-4129
[Abstract] [Full Text] -
Muller-Schiffmann, A., Beckmann, J., Steger, G.
(2006). The e6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms.. J. Virol.
80: 8718-8728
[Abstract] [Full Text] -
Borger, D. R., DeCaprio, J. A.
(2006). Targeting of p300/CREB Binding Protein Coactivators by Simian Virus 40 Is Mediated through p53. J. Virol.
80: 4292-4303
[Abstract] [Full Text] -
Parish, J. L., Kowalczyk, A., Chen, H.-T., Roeder, G. E., Sessions, R., Buckle, M., Gaston, K.
(2006). E2 Proteins from High- and Low-Risk Human Papillomavirus Types Differ in Their Ability To Bind p53 and Induce Apoptotic Cell Death. J. Virol.
80: 4580-4590
[Abstract] [Full Text] -
Wei, Q.
(2005). Pitx2a Binds to Human Papillomavirus Type 18 E6 Protein and Inhibits E6-mediated P53 Degradation in HeLa Cells. J. Biol. Chem.
280: 37790-37797
[Abstract] [Full Text] -
Zhang, Y., Fan, S., Meng, Q., Ma, Y., Katiyar, P., Schlegel, R., Rosen, E. M.
(2005). BRCA1 Interaction with Human Papillomavirus Oncoproteins. J. Biol. Chem.
280: 33165-33177
[Abstract] [Full Text] -
Liu, X., Yuan, H., Fu, B., Disbrow, G. L., Apolinario, T., Tomaic, V., Kelley, M. L., Baker, C. C., Huibregtse, J., Schlegel, R.
(2005). The E6AP Ubiquitin Ligase Is Required for Transactivation of the hTERT Promoter by the Human Papillomavirus E6 Oncoprotein. J. Biol. Chem.
280: 10807-10816
[Abstract] [Full Text] -
Magal, S. S., Jackman, A., Ish-Shalom, S., Botzer, L. E., Gonen, P., Schlegel, R., Sherman, L.
(2005). Downregulation of Bax mRNA expression and protein stability by the E6 protein of human papillomavirus 16. J. Gen. Virol.
86: 611-621
[Abstract] [Full Text] -
Routes, J. M., Morris, K., Ellison, M. C., Ryan, S.
(2005). Macrophages Kill Human Papillomavirus Type 16 E6-Expressing Tumor Cells by Tumor Necrosis Factor Alpha- and Nitric Oxide-Dependent Mechanisms. J. Virol.
79: 116-123
[Abstract] [Full Text] -
Meng, G., Zhao, Y., Nag, A., Zeng, M., Dimri, G., Gao, Q., Wazer, D. E., Kumar, R., Band, H., Band, V.
(2004). Human ADA3 Binds to Estrogen Receptor (ER) and Functions As a Coactivator for ER-mediated Transactivation. J. Biol. Chem.
279: 54230-54240
[Abstract] [Full Text] -
Malanchi, I., Accardi, R., Diehl, F., Smet, A., Androphy, E., Hoheisel, J., Tommasino, M.
(2004). Human Papillomavirus Type 16 E6 Promotes Retinoblastoma Protein Phosphorylation and Cell Cycle Progression. J. Virol.
78: 13769-13778
[Abstract] [Full Text] -
Munger, K., Baldwin, A., Edwards, K. M., Hayakawa, H., Nguyen, C. L., Owens, M., Grace, M., Huh, K.
(2004). Mechanisms of Human Papillomavirus-Induced Oncogenesis. J. Virol.
78: 11451-11460
[Full Text] -
Gewin, L., Myers, H., Kiyono, T., Galloway, D. A.
(2004). Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev.
18: 2269-2282
[Abstract] [Full Text] -
Lu, Z., Hu, X., Li, Y., Zheng, L., Zhou, Y., Jiang, H., Ning, T., Basang, Z., Zhang, C., Ke, Y.
(2004). Human Papillomavirus 16 E6 Oncoprotein Interferences with Insulin Signaling Pathway by Binding to Tuberin. J. Biol. Chem.
279: 35664-35670
[Abstract] [Full Text] -
Filippova, M., Parkhurst, L., Duerksen-Hughes, P. J.
(2004). The Human Papillomavirus 16 E6 Protein Binds to Fas-associated Death Domain and Protects Cells from Fas-triggered Apoptosis. J. Biol. Chem.
279: 25729-25744
[Abstract] [Full Text] -
Longworth, M. S., Laimins, L. A.
(2004). Pathogenesis of Human Papillomaviruses in Differentiating Epithelia. Microbiol. Mol. Biol. Rev.
68: 362-372
[Abstract] [Full Text] -
Oh, S. T., Longworth, M. S., Laimins, L. A.
(2004). Roles of the E6 and E7 Proteins in the Life Cycle of Low-Risk Human Papillomavirus Type 11. J. Virol.
78: 2620-2626
[Abstract] [Full Text] -
Tao, M., Kruhlak, M., Xia, S., Androphy, E., Zheng, Z.-M.
(2003). Signals That Dictate Nuclear Localization of Human Papillomavirus Type 16 Oncoprotein E6 in Living Cells. J. Virol.
77: 13232-13247
[Abstract] [Full Text] -
McMurray, H. R., McCance, D. J.
(2003). Human Papillomavirus Type 16 E6 Activates TERT Gene Transcription through Induction of c-Myc and Release of USF-Mediated Repression. J. Virol.
77: 9852-9861
[Abstract] [Full Text] -
Veldman, T., Liu, X., Yuan, H., Schlegel, R.
(2003). Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA
100: 8211-8216
[Abstract] [Full Text] -
Zeng, M., Kumar, A., Meng, G., Gao, Q., Dimri, G., Wazer, D., Band, H., Band, V.
(2002). Human Papilloma Virus 16 E6 Oncoprotein Inhibits Retinoic X Receptor-mediated Transactivation by Targeting Human ADA3 Coactivator. J. Biol. Chem.
277: 45611-45618
[Abstract] [Full Text] -
Nguyen, M., Song, S., Liem, A., Androphy, E., Liu, Y., Lambert, P. F.
(2002). A Mutant of Human Papillomavirus Type 16 E6 Deficient in Binding {alpha}-Helix Partners Displays Reduced Oncogenic Potential In Vivo. J. Virol.
76: 13039-13048
[Abstract] [Full Text] -
Muller, A., Ritzkowsky, A., Steger, G.
(2002). Cooperative Activation of Human Papillomavirus Type 8 Gene Expression by the E2 Protein and the Cellular Coactivator p300. J. Virol.
76: 11042-11053
[Abstract] [Full Text] -
Kumar, A., Zhao, Y., Meng, G., Zeng, M., Srinivasan, S., Delmolino, L. M., Gao, Q., Dimri, G., Weber, G. F., Wazer, D. E., Band, H., Band, V.
(2002). Human Papillomavirus Oncoprotein E6 Inactivates the Transcriptional Coactivator Human ADA3. Mol. Cell. Biol.
22: 5801-5812
[Abstract] [Full Text] -
Huang, S.-M., McCance, D. J.
(2002). Down Regulation of the Interleukin-8 Promoter by Human Papillomavirus Type 16 E6 and E7 through Effects on CREB Binding Protein/p300 and P/CAF. J. Virol.
76: 8710-8721
[Abstract] [Full Text] -
Filippova, M., Song, H., Connolly, J. L., Dermody, T. S., Duerksen-Hughes, P. J.
(2002). The Human Papillomavirus 16 E6 Protein Binds to Tumor Necrosis Factor (TNF) R1 and Protects Cells from TNF-induced Apoptosis. J. Biol. Chem.
277: 21730-21739
[Abstract] [Full Text] -
Gao, Q., Kumar, A., Singh, L., Huibregtse, J. M., Beaudenon, S., Srinivasan, S., Wazer, D. E., Band, H., Band, V.
(2002). Human Papillomavirus E6-induced Degradation of E6TP1 Is Mediated by E6AP Ubiquitin Ligase. Cancer Res.
62: 3315-3321
[Abstract] [Full Text] -
Noya, F., Chien, W.-M., Wu, X., Banerjee, N. S., Kappes, J. C., Broker, T. R., Chow, L. T.
(2002). The Promoter of the Human Proliferating Cell Nuclear Antigen Gene Is Not Sufficient for Cell Cycle-dependent Regulation in Organotypic Cultures of Keratinocytes. J. Biol. Chem.
277: 17271-17280
[Abstract] [Full Text] -
Bernat, A., Massimi, P., Banks, L.
(2002). Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. J. Gen. Virol.
83: 829-833
[Abstract] [Full Text] -
Nguyen, D. X., Westbrook, T. F., McCance, D. J.
(2002). Human Papillomavirus Type 16 E7 Maintains Elevated Levels of the cdc25A Tyrosine Phosphatase during Deregulation of Cell Cycle Arrest. J. Virol.
76: 619-632
[Abstract] [Full Text] -
Vogt Sionov, R., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., Haupt, Y.
(2001). c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination. Mol. Cell. Biol.
21: 5869-5878
[Abstract] [Full Text] -
Balague, C., Noya, F., Alemany, R., Chow, L. T., Curiel, D. T.
(2001). Human Papillomavirus E6E7-Mediated Adenovirus Cell Killing: Selectivity of Mutant Adenovirus Replication in Organotypic Cultures of Human Keratinocytes. J. Virol.
75: 7602-7611
[Abstract] [Full Text] -
Gao, Q., Singh, L., Kumar, A., Srinivasan, S., Wazer, D. E., Band, V.
(2001). Human Papillomavirus Type 16 E6-Induced Degradation of E6TP1 Correlates with Its Ability To Immortalize Human Mammary Epithelial Cells. J. Virol.
75: 4459-4466
[Abstract] [Full Text] -
Degenhardt, Y. Y., Silverstein, S. J.
(2001). Gps2, a Protein Partner for Human Papillomavirus E6 Proteins. J. Virol.
75: 151-160
[Abstract] [Full Text] -
Zimmermann, H., Koh, C.-H., Degenkolbe, R., O’Connor, M. J., Müller, A., Steger, G., Chen, J. J., Lui, Y., Androphy, E., Bernard, H.-U.
(2000). Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53. J. Gen. Virol.
81: 2617-2623
[Abstract] [Full Text] -
Dulic, V., Beney, G.-E., Frebourg, G., Drullinger, L. F., Stein, G. H.
(2000). Uncoupling between Phenotypic Senescence and Cell Cycle Arrest in Aging p21-Deficient Fibroblasts. Mol. Cell. Biol.
20: 6741-6754
[Abstract] [Full Text] -
Peng, Y.-C., Breiding, D. E., Sverdrup, F., Richard, J., Androphy, E. J.
(2000). AMF-1/Gps2 Binds p300 and Enhances Its Interaction with Papillomavirus E2 Proteins. J. Virol.
74: 5872-5879
[Abstract] [Full Text] -
Goodman, R. H., Smolik, S.
(2000). CBP/p300 in cell growth, transformation, and development. Genes Dev.
14: 1553-1577
[Full Text] -
Clark, E., Santiago, F., Deng, L., Chong, S. y., de la Fuente, C., Wang, L., Fu, P., Stein, D., Denny, T., Lanka, V., Mozafari, F., Okamoto, T., Kashanchi, F.
(2000). Loss of G1/S Checkpoint in Human Immunodeficiency Virus Type 1-Infected Cells Is Associated with a Lack of Cyclin-Dependent Kinase Inhibitor p21/Waf1. J. Virol.
74: 5040-5052
[Abstract] [Full Text] -
Wang, L., Grossman, S. R., Kieff, E.
(2000). Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc. Natl. Acad. Sci. USA
97: 430-435
[Abstract] [Full Text] -
Therrien, J.-P., Drouin, R., Baril, C., Drobetsky, E. A.
(1999). Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair. Proc. Natl. Acad. Sci. USA
96: 15038-15043
[Abstract] [Full Text] -
Hong, T.-M., Chen, J. J. W., Peck, K., Yang, P.-C., Wu, C.-W.
(2001). p53 Amino Acids 339-346 Represent the Minimal p53 Repression Domain. J. Biol. Chem.
276: 1510-1515
[Abstract] [Full Text] -
Cho, S., Tian, Y., Benjamin, T. L.
(2001). Binding of p300/CBP Co-activators by Polyoma Large T Antigen. J. Biol. Chem.
276: 33533-33539
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»